YOLFTbeta
Autolus Therapeutics Ltd

Autolus Therapeutics Ltd

AUTL · NASDAQ · Healthcare / Biotechnology

1.17USD-0.02 (-1.68%)

Price History

Full chart

Market Stats

Previous Close1.19
Open1.20
Day Range1.16 – 1.24
52-Week Range1.18 – 2.58
Volume1.80M
Market Cap493.73M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.06
Dividend Yield0.00%
Beta2.09
50-Day Avg1.98
200-Day Avg1.66

About

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Christian Martin Itin Ph.D.
  • Employees752
  • HeadquartersThe Mediaworks, London, United Kingdom, W12 7FP, USA
  • Websitehttps://www.autolus.com

Leadership

  • Dr. Christian Martin Itin Ph.D.CEO & Director · b. 1964
  • Dr. Martin Pule M.D., MBBSFounder, Senior VP & Chief Scientific Officer · b. 1972
  • Mr. Robert F. DolskiSenior VP & CFO · b. 1971
  • Mr. Christopher VannSenior VP & COO · b. 1965
  • Mr. Patrick McIlvennySenior VP of Finance, Chief Accounting Officer & Principal Accounting Officer · b. 1980
  • Ms. Miranda NevilleSenior VP & Chief Technology Officer · b. 1975
  • Mr. Alex DriggsSenior VP of Legal Affairs & General Counsel and Secretary · b. 1976
  • Mr. Alexander SwanSenior VP & Chief Human Resources Officer · b. 1965
  • Dr. Christopher Williams Ph.D.Senior VP & Chief Business Development Officer · b. 1980
  • Dr. Matthias Will M.D.Senior VP & Chief Development Officer · b. 1973

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-09-302018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue94.11K1.21M1.69M1.05M1.05M2.91M1.72M1.51M6.19M1.70M10.12M75.56M
Growth (%)-+1187.83%+39.69%-38.25%0.00%+178.19%-41.02%-12.13%+311.02%-72.59%+496.00%+646.68%
Cost of Revenue0478.00K1.01M48.30M48.30M105.42M134.89M128.65M137.22M6.57M141.02M96.59M
Gross Profit94.11K734.00K684.00K-47.25M-47.25M-102.51M-133.17M1.51M6.19M1.70M-130.90M-21.03M
Gross Margin100.00%60.56%40.40%-4520.40%-4520.40%-3525.10%-7765.19%100.00%100.00%100.00%-1293.48%-27.83%
Operating Expense8.20M15.11M24.10M10.28M10.28M145.07M169.96M141.88M149.09M181.40M110.53M260.41M
Operating Income-8.11M-14.38M-23.42M-57.53M-57.53M-247.58M-303.13M-140.37M-142.89M-179.70M-241.43M-281.44M
Operating Margin-8613.76%-1186.14%-1383.23%-5503.74%-5503.74%-8513.76%-17675.39%-9314.80%-2306.96%-10583.10%-2385.63%-372.45%
EBITDA-4.47M-13.90M-22.41M-35.21M-50.32M-137.40M-162.58M-132.47M-132.24M-156.77M-233.07M-250.26M
EBITDA Margin-4749.84%-1146.70%-1323.63%-3368.18%-4813.92%-4724.83%-9479.77%-8790.64%-2134.97%-9232.63%-2303.09%-331.18%
Net Income-7.46M-12.55M-19.73M-31.11M-31.11M-123.85M-142.09M-142.10M-148.84M-208.38M-220.66M-288.20M
Net Income Margin-7931.14%-1035.48%-1165.21%-2976.49%-2976.49%-4258.91%-8285.36%-9429.06%-2402.95%-12272.26%-2180.45%-381.40%
R&D2.17M10.44M16.01M24.64M24.64M105.62M134.99M110.84M117.35M130.48M158.14M128.59M
R&D as % of Total Revenue2308.54%861.06%945.78%2356.89%2356.89%3631.98%7871.02%7354.94%1894.64%7684.39%1562.61%170.17%
Interest Expense049.00K38.00K12.67K12.67K1.15M1.89M1.10M8.90M45.07M9.29M36.76M
Interest Expense % of Total Revenue0.00%4.04%2.24%1.21%1.21%39.48%110.09%73.32%143.77%2654.12%91.84%48.64%

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-09-302018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets22.66M34.18M148.66M217.66M217.66M303.53M294.24M405.56M490.27M375.38M782.73M589.07M
Total Liabilities1.95M3.49M6.06M12.52M12.52M48.69M84.20M92.24M191.60M263.91M355.40M410.94M
Total Equity20.71M30.69M142.60M205.14M205.14M254.84M210.03M313.32M298.67M111.47M427.32M178.13M
Cash10.18M28.06M137.07M189.30M189.30M211.43M154.09M310.34M382.44M239.57M227.38M104.13M
Total Debt-188.00K265.00K221.00K221.00K26.22M54.16M68.01M24.26M52.97M52.63M351.59M
Net Debt-10.18M-27.87M-136.81M-189.08M-189.08M-185.21M-99.92M-242.32M-358.18M-186.60M-174.75M247.45M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-09-302018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.33M-9.85M-16.36M-25.85M-25.85M-101.48M-117.76M-117.86M-112.31M-145.59M-206.27M-283.57M
Investing Cash Flow-754.14K-1.85M-2.88M-9.53M-7.65M-18.67M-14.68M-8.86M-10.84M-10.99M-394.55M158.46M
Financing Cash Flow12.23M32.22M127.69M117.49M117.49M108.86M74.42M284.06M223.61M-883.00K589.55M-4.34M
Capital Expenditure762.07K1.85M2.88M8.77M8.77M18.67M14.68M8.86M10.84M10.99M34.82M27.13M
Free Cash Flow-4.09M-11.70M-19.24M-34.62M-34.62M-120.15M-132.44M-126.72M-123.15M-156.57M-241.09M-310.70M
FCF to OCF122.92%118.83%117.58%133.94%133.94%118.40%112.47%107.51%109.65%107.55%116.88%109.57%

Earnings

Report DateJun 22, 2018Sep 26, 2018Feb 25, 2019May 14, 2019Aug 8, 2019Nov 7, 2019Mar 3, 2020May 7, 2020Aug 6, 2020Nov 5, 2020Mar 4, 2021May 6, 2021Aug 5, 2021Nov 3, 2021Mar 10, 2022May 5, 2022Aug 4, 2022Nov 3, 2022Mar 7, 2023May 4, 2023Aug 3, 2023Nov 2, 2023Mar 14, 2024May 17, 2024Aug 8, 2024Nov 12, 2024Mar 20, 2025May 8, 2025Aug 12, 2025Nov 12, 2025Mar 10, 2026May 14, 2026Aug 11, 2026Nov 11, 2026
EPS Estimate0.00-0.62-0.66-0.56-0.65-0.83-0.74-0.74-0.70-0.71-0.77-0.59-0.49-0.51-0.46-0.49-0.33-0.46-0.27-0.27-0.22-0.25-0.25-0.14-0.21-0.22-0.24-0.26-0.23-0.23-0.25-0.26-0.21-0.20
EPS Actual-0.57-0.83-0.52-0.69-0.65-0.61-0.84-0.60-0.62-0.72-0.83-0.53-0.47-0.47-0.51-0.41-0.46-0.47-0.23-0.23-0.26-0.26-0.45-0.24-0.22-0.31-0.09-0.26-0.18-0.30-0.34-0.27-0.15-
Surprise--34.68%21.21%-23.21%0.00%26.51%-13.51%18.92%11.43%-1.41%-7.79%10.17%4.08%7.84%-10.87%16.33%-39.39%-2.17%14.81%14.81%-18.18%-4.00%-80.00%-71.43%-4.76%-40.91%62.50%0.00%21.74%-30.43%-35.67%-3.85%28.57%-
TimingAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap493.73M
Enterprise Value400.90M
Trailing P/E0.00
Forward P/E0.00
Price / Sales4.21
Price / Book6.94
EPS-1.06
Book Value0.281
Revenue (TTM)117.39M
Gross Profit (TTM)-87.58M
EBITDA-236.57M
Profit Margin-238.65%
Operating Margin-95.95%
Return on Equity-133.00%
Return on Assets-25.44%
Shares Outstanding266.16M
Shares Float102.92M
Beta2.09
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 10 analystsTarget 8.73
  • Strong Buy
    8
  • Buy
    2

Ownership Breakdown

Institutions
63.43%
Insiders
18.09%
Retail / Other
18.48%

Top Institutional Holders

  • Mak Capital One LLC
    33.62M12.63%
  • Blackstone Inc
    20.49M7.70%
  • Syncona Portfolio Ltd.
    16.64M6.25%
  • Armistice Capital, LLC
    15.80M5.94%
  • Polygon Management Ltd
    9.50M3.57%
  • Schroder Investment Management Group
    7.83M2.94%
  • Frazier Life Sciences Management, L.P.
    4.45M1.67%
  • BNP Paribas Investment Partners SA
    3.36M1.26%
  • LAURION CAPITAL MANAGEMENT LP
    3.32M1.25%
  • Renaissance Technologies Corp
    2.30M0.86%
  • Bank of America Corp
    1.84M0.69%
  • BlackRock Inc
    1.48M0.56%
  • UBS Group AG
    1.31M0.49%
  • Millennium Management LLC
    1.22M0.46%
  • Cetera Investment Advisers
    1.13M0.42%
  • Balyasny Asset Management LLC
    971.69K0.37%
  • Morgan Stanley - Brokerage Accounts
    941.82K0.35%

Top Fund Holders

  • International Biotechnology Ord
    6.53M2.45%
  • AXA Framlington Health Fund - R Income
    3.36M1.26%
  • iShares Biotechnology ETF
    1.51M0.57%